Cargando…
Population Pharmacokinetics and Bayesian Dose Adjustment to Advance TDM of Anti-TB Drugs
Tuberculosis (TB) is still the number one cause of death due to an infectious disease. Pharmacokinetics and pharmacodynamics of anti-TB drugs are key in the optimization of TB treatment and help to prevent slow response to treatment, acquired drug resistance, and adverse drug effects. The aim of thi...
Autores principales: | Sturkenboom, Marieke G. G., Märtson, Anne-Grete, Svensson, Elin M., Sloan, Derek J., Dooley, Kelly E., van den Elsen, Simone H. J., Denti, Paolo, Peloquin, Charles A., Aarnoutse, Rob E., Alffenaar, Jan-Willem C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7935699/ https://www.ncbi.nlm.nih.gov/pubmed/33674941 http://dx.doi.org/10.1007/s40262-021-00997-0 |
Ejemplares similares
-
Fundament and Prerequisites for the Application of an Antifungal TDM Service
por: Brüggemann, Roger J. M., et al.
Publicado: (2015) -
Standard ganciclovir dosing results in slow decline of cytomegalovirus viral loads
por: Märtson, Anne-Grete, et al.
Publicado: (2021) -
Therapeutic Drug Monitoring of Ganciclovir: Where Are We?
por: Märtson, Anne-Grete, et al.
Publicado: (2022) -
Subtherapeutic Exposure of Ganciclovir in Children Despite Appropriate Dosing: A Short Communication
por: Marfil, Sjanene, et al.
Publicado: (2023) -
Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis
por: Stott, K E, et al.
Publicado: (2018)